Second malignancies in children with neuroblastoma after combined treatment with 131I-metaiodobenzylguanidine.
BACKGROUND
(131)I-metaiodobenzylguanidine ((131)I-MIBG) is selectively taken up by cells of neural crest origin, allowing targeted radiotherapy of tumors such as neuroblastoma (NB) and pheochromocytoma. Radiotherapy may provide additional benefits in the treatment of NB, with moderate side effects such as hematologic and thyroid toxicity. However, with longer follow-up, other complications might occur. We describe our experience with second cancers occurring in children treated with (131)I-MIBG and chemotherapy.


METHODS
The clinical records of 119 consecutive NB cases treated with (131)I-MIBG at a single institution between 1984 and 2001 were reviewed for the occurrence of a second malignant neoplasm (SMN).


RESULTS
Overall, five cases of SMN occurred in the study patients. In particular, two cases of myeloid leukemia, one of angiomatous fibrous histiocytoma, one of malignant schwannoma, and one case of rhabdomyosarcoma were detected. The schwannoma and the rhabdomyosarcoma developed within the residual neuroblastic mass after first-line therapy.


CONCLUSIONS
Should (131)I-MIBG treatment become more broadly employed in the therapeutic strategy for neuroblastoma, the risk of second cancer will have to be taken into consideration. The organization of an international registry of subjects treated with (131)I-MIBG might better define the frequency and features of second malignancies following this radiometabolic approach.
Garaventa
Alberto
A
Department of Pediatric Hematology/Oncology, G. Gaslini Children's Hospital, Genova, Italy. albertogaraventa@ospedale-gaslini.ge.it
Gambini
Claudio
C
Villavecchia
Giampiero
G
Di Cataldo
Andrea
A
Bertolazzi
Luigi
L
Pizzitola
Maria Rosa
MR
De Bernardi
Bruno
B
Haupt
Riccardo
R
D019797:3-Iodobenzylguanidine / Q000009:adverse effects / Q000627:therapeutic use*; D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007037:Hypothyroidism / Q000209:etiology; D007223:Infant; D008297:Male; D009381:Neoplasms, Radiation-Induced; D016609:Neoplasms, Second Primary; D009447:Neuroblastoma / Q000188:drug therapy / Q000532:radiotherapy*; D010524:Peripheral Nervous System Neoplasms / Q000188:drug therapy / Q000532:radiotherapy*; D019275:Radiopharmaceuticals / Q000009:adverse effects / Q000627:therapeutic use*; D015996:Survival Rate; D016896:Treatment Outcome
D019275:Radiopharmaceuticals; D019797:3-Iodobenzylguanidine